Cellnovo

About the deal

Paris, France, September 16th, 2016 – Cellnovo Group (“Cellnovo” CLNV: EN Paris or the “Company”), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, announces today that it has raised circa EUR 5.4 million from European and US institutional investors through a capital increase without preferential subscription rights.

In line with its participation in three major artificial pancreas projects and considering the estimated market potential, Cellnovo has chosen to accelerate the development and commercialisation of an artificial pancreas based on its mobile diabetes management system and micro-pump.